drugset / Trial / NCT02938572

A Randomised Proof-of-Principle Trial Investigating Pharmacodynamics, Pharmacokinetics, and Safety of NNC0143-0406 in Subjects With Type 1 Diabetes Mellitus

NCT02938572

Phase 1 Completed 47 enrolled Novo Nordisk A/S
RandomizedCrossoverDouble-blindTreatment

Summary

This trial is conducted in Europe. The aim of this trial is to investigate Pharmacodynamics (the effect of the investigated drug on the body) , Pharmacokinetics (the exposure of the trial drug in the body), and Safety of NNC0143-0406 in Subjects with Type 1 Diabetes Mellitus

Timeline

Start
2016-10-19
Primary completion
2017-06-17
Completion
2017-07-04

Drugs

EvaluationDrugModalityDoseRoute
Subject NNC0143-0406 Unknown Subcutaneous
Comparator insulin aspart Protein / enzyme biologic Subcutaneous